Table 3.
1-year, 3-year, and 5-year survival rates stratified by clinical features for PCCCL patients.
| Characteristics | Cancer specific survival | |||||
|---|---|---|---|---|---|---|
| 1-years survival | 95% CI | 3-years survival | 95% CI | 5-years survival | 95% CI | |
| Total | 0.595 | 0.55–0.65 | 0.393 | 0.34–0.45 | 0.299 | 0.25–0.36 |
| Age (years) | ||||||
| ≤60 | 0.565 | 0.49–0.65 | 0.417 | 0.34–0.51 | 0.348 | 0.27–0.45 |
| 61–70 | 0.656 | 0.57–0.75 | 0.434 | 0.35–0.55 | 0.327 | 0.24–0.45 |
| >70 | 0.574 | 0.49–0.67 | 0.312 | 0.23–0.42 | 0.219 | 0.14–0.35 |
| Gender | ||||||
| Female | 0.646 | 0.57–0.73 | 0.377 | 0.3–0.47 | 0.293 | 0.22–0.39 |
| Male | 0.565 | 0.51–0.63 | 0.408 | 0.35–0.48 | 0.304 | 0.24–0.39 |
| Race | ||||||
| White | 0.591 | 0.53–0.66 | 0.383 | 0.32–0.46 | 0.293 | 0.23–0.37 |
| Black | 0.468 | 0.34–0.65 | 0.348 | 0.23–0.54 | \ | \ |
| Marital status | ||||||
| Married | 0.659 | 0.6–0.73 | 0.460 | 0.39–0.54 | 0.395 | 0.33–0.48 |
| Single | 0.499 | 0.42–0.59 | 0.279 | 0.21–0.37 | 0.161 | 0.1–0.26 |
| Grade | ||||||
| Well | 0.654 | 0.55–0.79 | 0.450 | 0.33–0.61 | 0.323 | 0.21–0.51 |
| Moderately | 0.720 | 0.64–0.81 | 0.499 | 0.4–0.62 | 0.393 | 0.3–0.52 |
| Poor and undifferentiated | 0.725 | 0.6–0.88 | 0.356 | 0.23–0.55 | \ | \ |
| Tumor stage | ||||||
| T1 | 0.746 | 0.68–0.82 | 0.588 | 0.51–0.68 | 0.47 | 0.39–0.57 |
| T2 | 0.706 | 0.59–0.84 | 0.470 | 0.34–0.65 | \ | \ |
| T3 | 0.422 | 0.32–0.57 | 0.150 | 0.08–0.29 | 0.0501 | 0.01–0.19 |
| T4 | 0.400 | 0.31–0.52 | 0.170 | 0.1–0.29 | 0.0969 | 0.04–0.26 |
| Tumor size | ||||||
| ≤37 mm | 0.928 | 0.87–0.99 | 0.781 | 0.69–0.88 | 0.633 | 0.52–0.77 |
| 37–96 mm | 0.646 | 0.57–0.73 | 0.402 | 0.32–0.5 | 0.281 | 0.21–0.38 |
| >96 mm | 0.397 | 0.3–0.53 | 0.147 | 0.08–0.28 | \ | \ |
| Lymph node metastases | ||||||
| N0 | 0.659 | 0.61–0.72 | 0.442 | 0.39–0.51 | 0.34 | 0.28–0.41 |
| N1 | 0.240 | 0.1–0.56 | \ | \ | \ | \ |
| Distant metastases | ||||||
| M0 | 0.672 | 0.62–0.73 | 0.460 | 0.4–0.53 | 0.354 | 0.3–0.43 |
| M1 | 0.242 | 0.16–0.38 | 0.061 | 0.02–0.2 | \ | \ |
| Summary stage | ||||||
| Localized | 0.741 | 0.68–0.8 | 0.533 | 0.47–0.61 | 0.425 | 0.35–0.51 |
| Regional | 0.498 | 0.4–0.62 | 0.273 | 0.19–0.4 | 0.172 | 0.1–0.31 |
| Distance | 0.224 | 0.14–0.36 | 0.061 | 0.02–0.2 | \ | \ |
| TNM stage | ||||||
| I | 0.798 | 0.73–0.87 | 0.647 | 0.56–0.74 | 0.516 | 0.42–0.63 |
| II | 0.761 | 0.65–0.9 | 0.546 | 0.4–0.74 | \ | \ |
| III | 0.565 | 0.47–0.69 | 0.199 | 0.12–0.33 | 0.083 | 0.03–0.22 |
| IV | 0.224 | 0.14–0.36 | 0.092 | 0.04–0.22 | \ | \ |
| AFP level | ||||||
| Elevated | 0.535 | 0.47–0.62 | 0.315 | 0.25–0.4 | 0.272 | 0.21–0.36 |
| Normal | 0.803 | 0.7–0.92 | 0.612 | 0.48–0.78 | 0.386 | 0.25–0.61 |
| Surgery type | ||||||
| Local ablation | 0.841 | 0.71–1 | 0.725 | 0.55–0.95 | \ | \ |
| Resection | 0.854 | 0.79–0.93 | 0.627 | 0.53–0.74 | 0.481 | 0.38–0.61 |
| Transplant | 0.873 | 0.75–1 | \ | \ | \ | \ |
| Surgery (Y/N) | ||||||
| No | 0.430 | 0.37–0.5 | 0.192 | 0.14–0.26 | 0.1176 | 0.07–0.19 |
| Yes | 0.850 | 0.79–0.91 | 0.681 | 0.61–0.77 | 0.573 | 0.49–0.67 |
| Radiation | ||||||
| No | 0.600 | 0.55–0.65 | 0.403 | 0.35–0.46 | 0.316 | 0.26–0.38 |
| Yes | 0.523 | 0.36–0.76 | \ | \ | \ | \ |
| Chemotherapy | ||||||
| No | 0.562 | 0.51–0.63 | 0.434 | 0.38–0.5 | 0.349 | 0.29–0.42 |
| Yes | 0.667 | 0.59–0.76 | 0.310 | 0.23–0.42 | 0.234 | 0.16–0.35 |
PCCCL – primary clear cell carcinoma of the liver.